StockData
Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc. (PCRX) stock

PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3028% above fair value
$36.48+0.00 (0.00%)

Close on Nov 17, 2026Market cap $1.45BP/E 104.2Yield –

Pacira BioSciences ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Pacira BioSciences's ebitda for the twelve months ending Jun 30, 2026 was $105.03M. For fiscal 2025 it was $110.21M, up 1935.7% from the year before. Over ten years it grew 18.1% a year on average. The highest annual figure on record is $163.25M in fiscal 2023.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025$110.21M+1935.7%
FY2024Dec 31, 2024$5.41M-96.7%
FY2023Dec 31, 2023$163.25M+7.7%
FY2022Dec 31, 2022$151.53M+27.9%
FY2021Dec 31, 2021$118.47M+78.8%
FY2020Dec 31, 2020$66.26M+120.4%
FY2019Dec 31, 2019$30.06M+3.4%
FY2018Dec 31, 2018$29.08M–
FY2017Dec 31, 2017-$11.10M–
FY2016Dec 31, 2016-$19.11M-191.3%
FY2015Dec 31, 2015$20.93M+329.8%
FY2014Dec 31, 2014$4.87M–
FY2013Dec 31, 2013-$47.54M–
FY2012Dec 31, 2012-$43.65M–
FY2011Dec 31, 2011-$34.79M–
FY2010Dec 31, 2010-$18.64M–
FY2009Dec 31, 2009-$24.40M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$25.56M-28.6%
Q1 FY2026Mar 31, 2026$28.23M+21.9%
Q4 FY2025Dec 31, 2025$23.68M-48.5%
Q3 FY2025Sep 30, 2025$27.55M–
Q2 FY2025Jun 30, 2025$35.82M-24.0%
Q1 FY2025Mar 31, 2025$23.16M-26.8%
Q4 FY2024Dec 31, 2024$45.95M-11.0%
Q3 FY2024Sep 30, 2024-$119.27M-429.9%
Q2 FY2024Jun 30, 2024$47.10M-20.1%
Q1 FY2024Mar 31, 2024$31.64M+91.6%
Q4 FY2023Dec 31, 2023$51.65M+151.8%
Q3 FY2023Sep 30, 2023$36.15M-12.9%
Q2 FY2023Jun 30, 2023$58.93M+13.1%
Q1 FY2023Mar 31, 2023$16.51M-55.9%
Q4 FY2022Dec 31, 2022$20.51M+18.7%
Q3 FY2022Sep 30, 2022$41.49M+11.6%
Q2 FY2022Jun 30, 2022$52.10M+31.1%
Q1 FY2022Mar 31, 2022$37.43M+54.1%
Q4 FY2021Dec 31, 2021$17.28M-27.5%
Q3 FY2021Sep 30, 2021$37.16M+64.0%
Q2 FY2021Jun 30, 2021$39.74M–
Q1 FY2021Mar 31, 2021$24.29M+10.8%
Q4 FY2020Dec 31, 2020$23.84M+250.4%
Q3 FY2020Sep 30, 2020$22.66M+182.6%
Q2 FY2020Jun 30, 2020-$2.16M-120.4%
Q1 FY2020Mar 31, 2020$21.92M+368.4%
Q4 FY2019Dec 31, 2019$6.80M-58.3%
Q3 FY2019Sep 30, 2019$8.02M+6.2%
Q2 FY2019Jun 30, 2019$10.56M+12.4%
Q1 FY2019Mar 31, 2019$4.68M–
Q4 FY2018Dec 31, 2018$16.31M+34.6%
Q3 FY2018Sep 30, 2018$7.55M–
Q2 FY2018Jun 30, 2018$9.39M–
Q1 FY2018Mar 31, 2018-$4.18M–
Q4 FY2017Dec 31, 2017$12.12M+1417.3%
Q3 FY2017Sep 30, 2017-$211.00K–
Q2 FY2017Jun 30, 2017-$12.07M–
Q1 FY2017Mar 31, 2017-$10.95M–
Q4 FY2016Dec 31, 2016$799.00K–
Q3 FY2016Sep 30, 2016-$17.59M–

More Pacira BioSciences figures

See a number that looks wrong?